Document 2715
 DOCN  M94A2715
 TI    Comparative clinical evaluation of an anti-HIV 1 + 2 3.gen EIA with a
       HIV antigen EIA in seroconversion phase.
 DT    9412
 AU    Faatz E; Melchior W; Hess G; Jilek F; Babiel R; Boehringer Mannheim
       GmbH, Penzberg, Germany.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):241 (abstract no. PB0395). Unique
       Identifier : AIDSLINE ICA10/94369860
 AB    OBJECTIVE: Since the necessity of HIV antigen immunoassays for the
       detection of early seroconversion in blood banks is still discussed
       controversially, we did a comparative study of two HIV-antigen
       immunoassays and two anti-HIV immunoassays. The anti-HIV immunoassays
       were chosen to be those using a double antigen or bridging test concept,
       for this type of test concept theoretically is able to detect all immune
       globulin classes including IgM and is therefore considered to be the
       most sensitive type of antibody immunoassay in seroconversion. METHODS:
       The Boehringer Mannheim Enzymun-Test HIVAg, one competitor HIVAg EIA,
       the Boehringer Mannheim Enzymun-Test anti-HIV 3.generation and one
       competitor anti-HIV 3.generation EIA were used to evaluate 8
       seroconversion panels, the Boston Biomedica HIV antigen mixed titer
       panel and anti-HIV Low Titer Panel 104 and several other critical
       samples from different sources. RESULTS: The detection of positive
       samples is very comparable between the Enzymun-Test HIVAg and the
       competitor HIVAg EIA and the Boehringer Mannheim Enzymun-Test anti-HIV
       3.generation and the competitor anti-HIV 3.generation EIA respectively.
       With seroconversion panels I and L the first available bleed is positive
       in all four immunoassays. Since no earlier negative bleed is available
       with these panels no decision can be made which method would have
       detected these seroconversions earlier. The seroconversion panels E, P,
       Q, R, S, and NYBC Panel A are detected one to three bleeds earlier by
       the antigen assays, which is 7 to 51 days earlier than detection by
       anti-HIV 3.generation assays. DISCUSSION: The usefulness of a HIVAg
       screening assay for blood transfusion survey in addition to established
       anti-HIV screening assays will be discussed.
 DE    Blood Banks  Comparative Study  Human  HIV Antigens/*BLOOD  HIV
       Seropositivity/*DIAGNOSIS/IMMUNOLOGY  HIV-1/*IMMUNOLOGY
       HIV-2/*IMMUNOLOGY  *Immunoenzyme Techniques  Predictive Value of Tests
       MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).